TY - JOUR
T1 - Analysis of the structure and function of FOX-4 cephamycinase
AU - Lefurgy, S. T.
AU - Malashkevich, V. N.
AU - Aguilan, J. T.
AU - Nieves, E.
AU - Mundorff, E. C.
AU - Biju, B.
AU - Noel, M. A.
AU - Toro, R.
AU - Baiwir, D.
AU - Papp-Wallace, K. M.
AU - Almo, S. C.
AU - Frere, J. M.
AU - Bou, G.
AU - Bonomo, R. A.
N1 - Funding Information:
HHS | National Institutes of Health (NIH) provided funding to Vladimir N. Malashkevich, Steven C. Almo, and Robert A. Bonomo under grant numbers AI100560, AI063517, GM094662, 1S10RR029398, and 1S10RR019352. U.S. Department of Veterans Affairs (VA) provided funding to Robert A. Bonomo under grant number BX001974. DOE | Argonne National Laboratory, Office of Science (ANL) provided funding to Vladimir N. Malashkevich and Steven C. Almo under grant number DE-AC02-06CH11357. Crystallographic and mass spectrometric efforts were provided by the NYSGRC, which is supported by NIGMS grant no. U54 GM094662 to S.C.A. Mass spectrometry was also supported by grants NIH SIG 1S10RR029398 (Orbitrap) and 1S10RR019352 (LTQ). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract DE-AC02- 06CH11357. Use of the Lilly Research Laboratories Collaborative Access Team (LRL-CAT) beamline at sector 31 of the Advanced Photon Source was provided by the Eli Lilly Company, which operates the facility. R.A.B. is supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs and the Veterans Integrated Service Network 10 Geriatric Research, Education, and Clinical Center (VISN 10 GRECC). K.M.P.-W. is supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs and by the Veterans Affairs Merit Review Program Award 1I01BX002872. S.T.L. is supported by a Hofstra University Faculty Research and Development Grant.
Publisher Copyright:
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
PY - 2016/2
Y1 - 2016/2
N2 - Class C β-lactamases poorly hydrolyze cephamycins (e.g., cefoxitin, cefotetan, and moxalactam). In the past 2 decades, a new family of plasmid-based AmpC β-lactamases conferring resistance to cefoxitin, the FOX family, has grown to include nine unique members descended from the Aeromonas caviae chromosomal AmpC. To understand the basis for the unique cephamycinase activity in the FOX family, we determined the first X-ray crystal structures of FOX-4, apo enzyme and the acyl-enzyme with its namesake compound, cefoxitin, using the Y150F deacylation-deficient variant. Notably, recombinant expression of N-terminally tagged FOX-4 also yielded an inactive adenylylated enzyme form not previously observed in β-lactamases. The post-translational modification (PTM), which occurs on the active site Ser64, would not seem to provide a selective advantage, yet might present an opportunity for the design of novel antibacterial drugs. Substantial ligand-induced changes in the enzyme are seen in the acyl-enzyme complex, particularly the R2 loop and helix H10 (P289 to N297), with movement of F293 by 10.3 Å. Taken together, this study provides the first picture of this highly proficient class C cephamycinase, uncovers a novel PTM, and suggests a possible cephamycin resistance mechanism involving repositioning of the substrate due to the presence of S153P, N289P, and N346I substitutions in the ligand binding pocket.
AB - Class C β-lactamases poorly hydrolyze cephamycins (e.g., cefoxitin, cefotetan, and moxalactam). In the past 2 decades, a new family of plasmid-based AmpC β-lactamases conferring resistance to cefoxitin, the FOX family, has grown to include nine unique members descended from the Aeromonas caviae chromosomal AmpC. To understand the basis for the unique cephamycinase activity in the FOX family, we determined the first X-ray crystal structures of FOX-4, apo enzyme and the acyl-enzyme with its namesake compound, cefoxitin, using the Y150F deacylation-deficient variant. Notably, recombinant expression of N-terminally tagged FOX-4 also yielded an inactive adenylylated enzyme form not previously observed in β-lactamases. The post-translational modification (PTM), which occurs on the active site Ser64, would not seem to provide a selective advantage, yet might present an opportunity for the design of novel antibacterial drugs. Substantial ligand-induced changes in the enzyme are seen in the acyl-enzyme complex, particularly the R2 loop and helix H10 (P289 to N297), with movement of F293 by 10.3 Å. Taken together, this study provides the first picture of this highly proficient class C cephamycinase, uncovers a novel PTM, and suggests a possible cephamycin resistance mechanism involving repositioning of the substrate due to the presence of S153P, N289P, and N346I substitutions in the ligand binding pocket.
UR - http://www.scopus.com/inward/record.url?scp=84957921615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957921615&partnerID=8YFLogxK
U2 - 10.1128/AAC.01887-15
DO - 10.1128/AAC.01887-15
M3 - Article
C2 - 26525784
AN - SCOPUS:84957921615
SN - 0066-4804
VL - 60
SP - 717
EP - 728
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 2
ER -